William Blair Upgrades PacBio Shares on Technology Improvements, Expanded Applications | GenomeWeb

NEW YORK(GenomeWeb) – William Blair today upgraded shares of Pacific Biosciences to Outperform, citing improvements to the company's technology, expanded application for its instruments, and its deal with Roche.

The investment bank previously had a Market Perform rating on the Menlo Park, California-based next-generation sequencing company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

Sponsored by
New England BioLabs

This webinar will provide an update on Phase 2 of the ongoing ABRF Next Generation Sequencing Study, an effort to evaluate the performance of NGS platforms and to identify optimal methods and best practices. Phase 1 of the study focused on RNA sequencing, while Phase 2 is focusing on genomic DNA samples.

Sponsored by
Agilent Technologies

This webinar will provide specific use cases from a molecular pathology lab demonstrating how an automated bioinformatics pipeline can improve somatic variant assessment and reporting.

Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.